<DOC>
	<DOCNO>NCT02477332</DOCNO>
	<brief_summary>This placebo active-controlled phase 2b dose-finding study evaluate efficacy safety QGE031 monthly subcutaneous injection add-on therapy patient Chronic Spontaneous Urticaria .</brief_summary>
	<brief_title>Dose-finding Study QGE031 add-on Therapy Evaluate Efficacy Safety Patients With CSU</brief_title>
	<detailed_description />
	<mesh_term>Urticaria</mesh_term>
	<mesh_term>Omalizumab</mesh_term>
	<criteria>Diagnosis chronic spontaneous urticaria least 6 month Diagnosis chronic spontaneous urticaria refractory standard care time randomization Clearly define underlie etiology chronic urticaria chronic spontaneous urticaria Evidence parasitic infection Any skin disease chronic spontaneous urticaria chronic itch Previous treatment omalizumab QGE031 Contraindications hypersensitivity fexofenadine , loratadine , cetirizine , epinephrine History anaphylactic shock History current diagnosis ECG abnormalities indicate significant risk safety patient participate study History hypersensitivity study drug component similar chemical class Pregnant nursing ( lactate ) woman Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>QGE031</keyword>
	<keyword>omalizumab</keyword>
	<keyword>chronic</keyword>
	<keyword>spontaneous</keyword>
	<keyword>urticaria</keyword>
	<keyword>adult</keyword>
	<keyword>CSU</keyword>
</DOC>